Roche Holding AG (WBO:ROGP) Long-Term Debt: €29,395 Mil (As of Dec. 2025)


WBO:ROGP Roche Holding AG WBO:ROGP
54 GF Score
Price €372.00
GF Value €288.76
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Long-Term Debt?

Roche Holding AG WBO:ROGP +4.20% 54 Long-Term Debt is €29,395 Mil as of Dec. 2025. GuruFocus rates WBO:ROGP with a GF Score™ of 54/100 and a GF Value™ of €288.76 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG's Long-Term Debt for the quarter that ended in Dec. 2025 was €29,395 Mil.

Roche Holding AG's quarterly Long-Term Debt declined from Dec. 2024 (€32,907 Mil) to Jun. 2025 (€28,215 Mil) but then increased from Jun. 2025 (€28,215 Mil) to Dec. 2025 (€29,395 Mil).

Roche Holding AG's annual Long-Term Debt increased from Dec. 2023 (€26,308 Mil) to Dec. 2024 (€32,907 Mil) but then declined from Dec. 2024 (€32,907 Mil) to Dec. 2025 (€29,395 Mil).

Roche Holding AG  (WBO:ROGP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Roche Holding AG Long-Term Debt Related Terms

Roche Holding AG Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Long-Term Debt Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,447.62 21,675.72 26,307.55 32,906.58 29,395.43

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26,307.55 29,539.25 32,906.58 28,214.82 29,395.43
WBO:ROGP
54GF Score
Roche Holding AG WBO:ROGP
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €29,395 Mil mean?
Roche Holding AG (WBO:ROGP) has a Long-Term Debt of €29,395 Mil as of Dec. 2025.
Is Roche Holding AG's Long-Term Debt too high?
Roche Holding AG's current Long-Term Debt is €29,395 Mil. Overall, Roche Holding AG has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Long-Term Debt compare to LLY and JNJ?
Roche Holding AG's Long-Term Debt of €29,395 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Roche Holding AG's current Long-Term Debt is €29,395 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (WBO:ROGP) is currently considered Modestly Overvalued. The stock's GF Value™ is €288.76, compared to a current price of €372.00 — trading 28.8% above its estimated fair value. The current Long-Term Debt is €29,395 Mil. Roche Holding AG's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Roche Holding AG (WBO:ROGP), the current Long-Term Debt is €29,395 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (WBO:ROGP) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €372.00 is trading 28.8% above its estimated GF Value™ of €288.76. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for WBO:ROGP:

  • Long-Term Debt: €29,395 Mil
  • GF Value™: €288.76 vs. price of €372.00 (28.8% above fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the WBO:ROGP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
54GF Score

Get the complete analysis for WBO:ROGP

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€372.00
Price
€288.76
GF Value